RegeneRx Licensee Receives FDA Permission to Conduct a Phase 3 Trial of RGN-137
RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its licensee for RGN-137,…
Read More...
Read More...
